MedTrace Logo

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

NCT06880523 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Conditions

Interventions

DRUG

STRIDE (durvalumab + tremelimumab)

As first treatment

DRUG

Durvalumab

monotherapy every 4 weeks

DRUG

Lenvatinib

Daily

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • National Cancer Institute, Naples

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Vincent Tam · Arthur J.E. Child Comprehensive Cancer Centre, Calgary AB, Canada

  • Jennifer Knox · University Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada

  • Marilina Piccirillo · NCI-Naples, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-21
Primary Completion
2028-01-31
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06880523 on ClinicalTrials.gov